{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:18:00Z","timestamp":1790781480892,"version":"4.1.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Findings from early phase studies are not always placed in the public domain. This study aims to explore why many early phase clinical oncology studies are not published, as well as identify the potential barriers investigators encountered in the publication process.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Semi-structured interviews were conducted among investigators with experience in early phase clinical oncology studies. Interviews were analyzed using reflexive thematic analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty-one investigators were interviewed. The majority worked in Europe (n\u2005=\u200513), while other investigators were based in North America (n\u2005=\u20054), Asia (n\u2005=\u20052) or Oceania (n\u2005=\u20052). We identified three reasons why investigators believed publishing early phase clinical trial results was important: (1) there is an ethical and moral responsibility; (2) there should be no loss of knowledge to society; and (3) there should be no waste of resources. Four main barriers in the publication process of early phase clinical trials were identified: (1) practical barriers (eg, an increased complexity of number of trials\/trial sites), (2) insufficient resources (eg, money, time and human), (3) limited motivation (eg, limited intrinsic motivation of the investigator or limited prospect of return for the sponsor), and (4) inadequate collaboration (eg, different interests between industry partners and investigators). Finally, five\u00a0major stakeholders were identified that can potentially contribute to improving the publication process: (1) journal editors, (2) sponsors, (3) investigators, (4) regulatory bodies, and (5) society. Investigator suggestions for improving this process, for each stakeholder, are presented.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study highlights the barriers experienced in publishing early phase clinical trials. Recognizing and acknowledging these barriers is crucial to devise effective strategies to improve the publishing and public sharing of early phase clinical trials.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf042","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T09:34:30Z","timestamp":1745487270000},"source":"Crossref","is-referenced-by-count":3,"title":["Barriers to publishing early phase clinical trials: the oncologists\u2019 perspective"],"prefix":"10.1093","volume":"30","author":[{"given":"Merel J J","family":"Lucassen","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, The Netherlands Cancer Institute , Amsterdam 1066CX ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Bergmann","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust , London SW3 6JJ ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1387-8686","authenticated-orcid":false,"given":"Olga","family":"Husson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Netherlands Cancer Institute , Amsterdam 1066CX ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1503-3123","authenticated-orcid":false,"given":"Udai","family":"Banerji","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research , London SW7 3RP ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3562-2868","authenticated-orcid":false,"given":"Bristi","family":"Basu","sequence":"additional","affiliation":[{"name":"University of Cambridge and Cambridge University Hospitals NHS Foundation Trust , Cambridge CB2 1TN ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-348X","authenticated-orcid":false,"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[{"name":"Clinica Universidad de Navarra, CIMA and CIBERONC , Pamplona 31008 ,","place":["Spain"]},{"name":"Nuffeld Department of Medicine, University of Oxford , Oxford OX3 7BN ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4921-829X","authenticated-orcid":false,"given":"Emiliano","family":"Calvo","sequence":"additional","affiliation":[{"name":"START Madrid-CIOCC, Centro Integral Oncol\u00f3gico Clara Campal , Madrid 28050 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe A","family":"Cassier","sequence":"additional","affiliation":[{"name":"Centre L\u00e9on B\u00e9rard , Lyon 69008 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6806-9061","authenticated-orcid":false,"given":"Alexander","family":"Drilon","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center , New York, NY 10065 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C","family":"Fong","sequence":"additional","affiliation":[{"name":"Auckland City Hospital and the University of Auckland , Auckland 1023 ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4412-7842","authenticated-orcid":false,"given":"Elena","family":"Garralda","sequence":"additional","affiliation":[{"name":"Val d\u2019Hebron Institute of Oncology , Barcelona 08035 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M","family":"Joshua","sequence":"additional","affiliation":[{"name":"Kinghorn Cancer Centre, St Vincent\u2019s University Hospital , Sydney NSW 2010 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2573-5789","authenticated-orcid":false,"given":"Chia-Chi","family":"Lin","sequence":"additional","affiliation":[{"name":"National Taiwan University Hospital , Taipei 10617 ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8321-4212","authenticated-orcid":false,"given":"Juanita","family":"Lopez","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust , London SW3 6JJ ,","place":["United Kingdom"]},{"name":"The Institute of Cancer Research , London SW7 3RP ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6099-4236","authenticated-orcid":false,"given":"Victor","family":"Moreno","sequence":"additional","affiliation":[{"name":"START Madrid-FJD, Hospital Universitario Fundacion Jimenez Diaz , Madrid 28040 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9339-7101","authenticated-orcid":false,"given":"Anna","family":"Minchom","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust , London SW3 6JJ ,","place":["United Kingdom"]},{"name":"The Institute of Cancer Research , London SW7 3RP ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0107-1444","authenticated-orcid":false,"given":"Ruth","family":"Plummer","sequence":"additional","affiliation":[{"name":"Northern Centre for Cancer Care, Newcastle University , Newcastle upon Tyne NE7 7DN ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5562-1857","authenticated-orcid":false,"given":"Sophie","family":"Postel-Vinay","sequence":"additional","affiliation":[{"name":"Gustave Roussy and Paris-Saclay University , Villejuif 94800 ,","place":["France"]},{"name":"University College of London Cancer Institute , London WC1E 6DD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3034-3042","authenticated-orcid":false,"given":"Anna","family":"Spreafico","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network , Toronto, ON M5G 2M9 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6632-0638","authenticated-orcid":false,"given":"Toshio","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Kansai Medical University Hospital , Osaka 573-1191 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A","family":"Yap","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center , Houston, TX 77030 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6715-2514","authenticated-orcid":false,"given":"Christina","family":"Yap","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research , London SW7 3RP ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann S","family":"De Bono","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust , London SW3 6JJ ,","place":["United Kingdom"]},{"name":"The Institute of Cancer Research , London SW7 3RP ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2989-2279","authenticated-orcid":false,"given":"Neeltje","family":"Steeghs","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Netherlands Cancer Institute , Amsterdam 1066CX ,","place":["The Netherlands"]},{"name":"University Medical Center Utrecht , Utrecht 3584 CX ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"2025042405342026700_CIT0001","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World medical association declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"2025042405342026700_CIT0002","doi-asserted-by":"publisher","first-page":"f6104","DOI":"10.1136\/bmj.f6104","article-title":"Non-publication of large randomized clinical trials: cross sectional analysis","volume":"347","author":"Jones","year":"2013","journal-title":"BMJ"},{"key":"2025042405342026700_CIT0003","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(07)60894-0","article-title":"Clinical trial registration: looking back and moving ahead","volume":"369","author":"Laine","year":"2007","journal-title":"Lancet (London, England)"},{"key":"2025042405342026700_CIT0004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41562-022-01499-0","article-title":"Lessons learnt from registration of biomedical research","volume":"7","author":"Serghiou","year":"2023","journal-title":"Nat Hum Behav"},{"key":"2025042405342026700_CIT0005","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0140-6736(19)33220-9","article-title":"Compliance with legal requirement to report clinical trial results on clinicaltrials.Gov: a cohort study","volume":"395","author":"DeVito","year":"2020","journal-title":"Lancet"},{"key":"2025042405342026700_CIT0006","year":"2024"},{"issue":"183","key":"2025042405342026700_CIT0007","first-page":"64982","article-title":"Clinical trials registration and results information submission; In: Department HHS ed: 2016-22129 (81 FR 64982)","volume":"81","author":"Collins","year":"2016","journal-title":"Fed Regist"},{"key":"2025042405342026700_CIT0008","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.clinthera.2024.01.002","article-title":"Phase I studies: innovations and issues","volume":"46","author":"Beninger","year":"2024","journal-title":"Clin Ther"},{"key":"2025042405342026700_CIT0009","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s10637-017-0549-6","article-title":"Comparison of published and unpublished phase I clinical cancer trials: an analysis of the clinicltrials.Gov database","volume":"36","author":"Shepshelovich","year":"2018","journal-title":"Invest New Drugs"},{"key":"2025042405342026700_CIT0010","doi-asserted-by":"publisher","first-page":"158","DOI":"10.7326\/0003-4819-153-3-201008030-00006","article-title":"Outcome reporting among drug trials registered in clinicaltrials.Gov","volume":"153","author":"Bourgeois","year":"2010","journal-title":"Ann Intern Med."},{"key":"2025042405342026700_CIT0011","doi-asserted-by":"publisher","first-page":"e230","DOI":"10.1371\/journal.pmed.0050230","article-title":"Bias, spin, and misreporting: time for full access to trial protocols and results","volume":"5","author":"Chan","year":"2008","journal-title":"PLoS Med"},{"key":"2025042405342026700_CIT0012","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/ijc.34181","article-title":"Eventual success rate and predictors of success for oncology drugs tested in phase I trials","volume":"152","author":"Haslam","year":"2023","journal-title":"Int J Cancer"},{"key":"2025042405342026700_CIT0013","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1002\/cncr.21337","article-title":"Presentation and subsequent publication rates of phase I oncology clinical trials","volume":"104","author":"Camacho","year":"2005","journal-title":"Cancer"},{"key":"2025042405342026700_CIT0014","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1634\/theoncologist.2015-0516","article-title":"Assessing the eventual publication of clinical trial abstracts submitted to a large annual oncology meeting","volume":"21","author":"Massey","year":"2016","journal-title":"Oncologist"},{"key":"2025042405342026700_CIT0015","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1158\/1078-0432.CCR-07-4886","article-title":"Improving the quality of abstract reporting for phase I cancer trials","volume":"14","author":"Strevel","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2025042405342026700_CIT0016","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/j.annonc.2022.01.018","article-title":"53p assessing the reporting quality of early phase dose-finding trials","volume":"33","author":"Yap","year":"2022","journal-title":"Ann Oncol"},{"key":"2025042405342026700_CIT0017","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol."},{"key":"2025042405342026700_CIT0018","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14767430.2021.1894909","article-title":"A realist approach to thematic analysis: making sense of qualitative data through experiential, inferential and dispositional themes","volume":"20","author":"Wiltshire","year":"2021","journal-title":"J Crit Real."},{"key":"2025042405342026700_CIT0019","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/2159676x.2019.1704846","article-title":"To saturate or not to saturate? Questioning data saturation as a useful concept for thematic analysis and sample-size rationales","volume":"13","author":"Braun","year":"2021","journal-title":"Qual Res Sport, Exerc Health"},{"key":"2025042405342026700_CIT0020","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/d41573-024-00048-w","article-title":"Shifts in the clinical trial landscape","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat Rev Drug Discovery"},{"key":"2025042405342026700_CIT0021","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"2025042405342026700_CIT0022","first-page":"1","article-title":"New clinical development success rates 2011-2020 report: Biotechnology Innovation Organization, Informa Pharma Intelligence","volume":"34","author":"Thomas","year":"2021","journal-title":"QLS Advisors"},{"key":"2025042405342026700_CIT0023","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrd.2017.70","article-title":"How much do clinical trials cost","volume":"16","author":"Martin","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2025042405342026700_CIT0024","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1740774515625964","article-title":"Key cost drivers of pharmaceutical clinical trials in the united states","volume":"13","author":"Sertkaya","year":"2016","journal-title":"Clin Trials"},{"key":"2025042405342026700_CIT0025","doi-asserted-by":"publisher","first-page":"e71966","DOI":"10.1371\/journal.pone.0071966","article-title":"Stock market returns and clinical trial results of investigational compounds: an event study analysis of large biopharmaceutical companies","volume":"8","author":"Hwang","year":"2013","journal-title":"PLoS One"},{"key":"2025042405342026700_CIT0026","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1093\/jnci\/djr338","article-title":"Company stock prices before and after public announcements related to oncology drugs","volume":"103","author":"Rothenstein","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2025042405342026700_CIT0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-019-1391-9","article-title":"When to keep it simple\u2013adaptive designs are not always useful","volume":"17","author":"Wason","year":"2019","journal-title":"BMC Med"},{"key":"2025042405342026700_CIT0028","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41571-023-00853-z","article-title":"Optimizing the FDA\u2019S project Optimus: opportunities and challenges","volume":"21","author":"Rodney","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2025042405342026700_CIT0029","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/psp4.13079","article-title":"Realizing the promise of project Optimus: challenges and emerging opportunities for dose optimization in oncology drug development","volume":"13","author":"Gao","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2025042405342026700_CIT0030","doi-asserted-by":"publisher","first-page":"e076386","DOI":"10.1136\/bmj-2023-076386","article-title":"Enhancing quality and impact of early phase dose-finding clinical trial protocols: spirit dose-finding extension (spirit-define) guidance","volume":"383","author":"Yap","year":"2023","journal-title":"BMJ"},{"key":"2025042405342026700_CIT0031","doi-asserted-by":"publisher","first-page":"e076387","DOI":"10.1136\/bmj-2023-076387","article-title":"Enhancing reporting quality and impact of early phase dose-finding clinical trials: consort dose-finding extension (consort-define) guidance","volume":"383","author":"Yap","year":"2023","journal-title":"BMJ"},{"key":"2025042405342026700_CIT0032","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1634\/theoncologist.2013-0247","article-title":"Clinical trial results: sharing results, speeding discoveries","volume":"18","author":"Fojo","year":"2013","journal-title":"Oncologist"},{"key":"2025042405342026700_CIT0033","doi-asserted-by":"publisher","first-page":"e1001","DOI":"10.1634\/theoncologist.2020-0455","article-title":"Accrual, publication bias, and the coronavirus in 2020","volume":"25","author":"Bates","year":"2020","journal-title":"Oncologist"},{"key":"2025042405342026700_CIT0034","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1477-5751-1-2","article-title":"Editorial: Journal of negative results in biomedicine","volume":"1","author":"Pfeffer","year":"2002","journal-title":"J Negat Results Biomed"},{"key":"2025042405342026700_CIT0035","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1001\/jama.2014.10716","article-title":"Sharing and reporting the results of clinical trials","volume":"313","author":"Hudson","year":"2015","journal-title":"JAMA"},{"key":"2025042405342026700_CIT0036","author":"International Clinical Trials Registry Platform (ICTRP) search portal version 3.6"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/4\/oyaf042\/62996685\/oyaf042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/4\/oyaf042\/62996685\/oyaf042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T09:34:32Z","timestamp":1745487272000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf042\/8118936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf042","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,4]]},"article-number":"oyaf042"}}